botulism immune globulin

botulism immune globulin

(botyoo-lism im-yoonglob-yoo-lin) ,


(trade name)


Therapeutic: vaccines immunizing agents
Pharmacologic: immune globulins
Pregnancy Category: UK


Infant botulism caused by type A or B toxin in children <1 yr.


Contains antibodies capable of neutralizing neurotoxins type A and B.

Therapeutic effects

Decreased sequelae of infant botulism.


Absorption: IV administration results in complete bioavailabilty.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: 28 days (infants).

Time/action profile (presence of neutralizing antibodies)

IV rapidend of instionup to 6 mos


Contraindicated in: History of severe reactions to other immunoglobulins; Selective immunoglobulin A deficiency.
Use Cautiously in: Pre-existing renal impairment, diabetes mellitus, volume depletion, sepsis, paraproteinemia, concurrent nephrotoxic agents (↑ risk of adverse renal reactions; use lowest concentration and slowest infusion rate).

Adverse Reactions/Side Effects


  • rash


  • infusion reactions


Drug-Drug interaction

May interfere with immune response to live-virus vaccines ; defer for at least 5 mo.


Intravenous (Children <1 yr) 1 mL/kg (50 mg/kg) as a single infusion.


Lyophilized powder for injection (requires reconstitution): 100 mg/vial

Nursing implications

Nursing assessment

  • Monitor vital signs continuously during infusion. If minor side effects occur, slow infusion rate. If anaphylaxis or hypotension occur, discontinue infusion and administer epinephrine.
  • Monitor urine output during therapy.
  • Monitor for signs of aseptic meningitis syndrome (AMS) (severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, vomiting). May occur within several hours to 2 days of infusion. Cerebrospinal fluid is frequently positive for pleocytosis and elevated protein levels. More frequent with high total doses (2g/kg) and may resolve with discontinuation of therapy.
  • Lab Test Considerations: Monitor renal function (BUN, serum creatinine) prior to and periodically during therapy.

Potential Nursing Diagnoses

Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Do not confuse BabyBIG with HBIG.
  • Correct volume depletion prior to therapy.
  • Intravenous Administration
  • Reconstitute lyophilized powder with 2 mL of sterile water for injection. Use a double-ended transfer needle or large syringe. If double-ended transfer needle used, insert one end first into vial of sterile water. Lyophilized powder is supplied in an evacuated vial and water should transfer via suction (aim jet of water to side of vial). After water is transferred into vial, release residual vacuum to hasten dissolution. Rotate container gently to wet all powder. Do not shake vial; will cause foaming. Concentration: 50 mg/mL. Solution is colorless; do not administer if discolored or contains particulate matter. After reconstitution, enter vial only once for administration. Begin infusion within 2 hr and complete within 4 hr of reconstitution.
  • Rate: Use an in-line or syringe-tip disposable filter (18 micron) during administration. Begin infusion slowly at 0.5 cc/kg/hr (25 mg/kg/hr). If no untoward reactions occur after 15 min, may increase rate to 1.0 cc/kg/hr (50 mg/kg/hr). Do not exceed 1 mL/kg/hr (50 mg/kg/hr). Monitor patient closely after each rate change. Infusion should take 67.5 minutes total.
  • Y-Site Compatibility: Administer through separate IV line or piggyback in lines containing 0.9% NaCl, D5W, D10W, D2.5W. D20W, D5/0.9% NaCl, or D5/0.45% NaCl. If administered through a pre-existing line, do not dilute more than 1:2.
  • Additive Incompatibility: Do not admix with other medications

Patient/Family Teaching

  • Inform parents of purpose of medication.
  • Caution parents to avoid live vaccinations shortly before or within 5 mo of administration.

Evaluation/Desired Outcomes

  • Decreased sequelae of infant botulism.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
(2006) Human botulism immune globulin for the treatment of infant botulism.
A human-derived botulism antitoxin, termed "botulism immune globulin" (144), has been prepared, and a clinical trial of its efficacy when given early in the course of illness is in progress in California.
Creation and development of the public service orphan drug human botulism immune globulin. Pediatrics 2007; 119 : 785-9.
The infant did not receive Human Botulism Immune Globulin (BabyBIG[R]) because of a delay in diagnosis and contacting the Local or State Public Health Department.
The patient was treated with Botulism Immune Globulin Intravenous (human) (BIG-IV) and discharged after 20 days; the infant recovered fully.